On December 20, 2024, Novo Nordisk reported that its CagriSema treatment led to 22.7% weight loss after 68 weeks, outperforming cagrilintide (11.8%) and semaglutide (16.1%). The phase 3 REDEFINE 1 trial included 3,417 participants with obesity or overweight, confirming the treatment's potential effectiveness.